Forge Biologics

Columbus, OH
AAV
3 confirmed programs · 1 sponsors · Last scored 2026-03-15
72.4
Signal Score
○ FDA Inspections ✓ Clinical Trials (3) ○ SEC Filings ✓ Press (12)

Quick Facts: Forge Biologics

Signal Score
72.4/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Columbus, OH
Modalities
AAV
Active CGT Programs
3 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 84.2
3 active programs across 1 sponsors
Modalities: AAV
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
3 active programs across 1 sponsors · Modalities: AAV · 2 programs in advanced phases (Phase 2/3)
Programs 3
Sponsors1
ModalitiesAAV
3 active programs across 1 sponsors
Modalities: AAV
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT06308718 Long-term Follow-up Study to Evaluate Safety and Efficacy of... NA Terminated
NCT05739643 Gene Transfer Clinical Trial for Infantile and Late Infantile... PHASE1/PHASE2 Active Not Recruiting
NCT04693598 Gene Transfer Clinical Trial for Krabbe Disease PHASE1/PHASE2 Active Not Recruiting
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 75.0
Strong parent backing: Ajinomoto Bio-Pharma Services (acquired $620M)
Source: SEC EDGAR, press monitoring
Subsidiary of Ajinomoto Bio-Pharma Services
SEC FilingsParent: Ajinomoto Bio-Pharma Services
Strong parent backing: Ajinomoto Bio-Pharma Services (acquired $620M)
Capacity 55.0
1 CGT manufacturing site: Columbus, OH
Modalities: AAV
Capacity assessment: 55.0/100
Sites: Columbus, OH
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
StatusExpanding
1 CGT manufacturing site: Columbus, OH
Modalities: AAV
Capacity assessment: 55.0/100
Sites: Columbus, OH
Recent Press12 articles
1 CGT manufacturing site: Columbus, OH
Modalities: AAV
Capacity assessment: 55.0/100

Recent News 12 articles

general 2026-03-04
Forge Biologics Agrees to Develop and Manufacture Gene Therapy for Progeria - Genetic Engineering and Biotechnology News
Forge Biologics Agrees to Develop and Manufacture Gene Therapy for Progeria  Genetic Engineering and Biotechnology News
Source →
partnership 2026-03-03
Press Release Service: The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria - CRISPR Medicine News
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria  CRISPR Medicine News
Source →
general 2026-03-03
Progeria Research Foundation, Forge Biologics Enter Gene Therapy Mfg. Pact - Contract Pharma
Progeria Research Foundation, Forge Biologics Enter Gene Therapy Mfg. Pact  Contract Pharma
Source →
partnership 2026-03-03
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria - Business Wire
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria  Business Wire
Source →
general 2026-03-01
Forge Biologics Emphasizes Gene Therapy Focus and Rare Disease Mission - TipRanks
Forge Biologics Emphasizes Gene Therapy Focus and Rare Disease Mission  TipRanks
Source →
general 2026-02-28
Forge Biologics Emphasizes Gene Therapy Focus on Rare Diseases - TipRanks
Forge Biologics Emphasizes Gene Therapy Focus on Rare Diseases  TipRanks
Source →
general 2026-02-27
Forge Biologics Highlights Power Resilience at Gene Therapy Manufacturing Facility - TipRanks
Forge Biologics Highlights Power Resilience at Gene Therapy Manufacturing Facility  TipRanks
Source →
capacity 2026-02-18
Forge Biologics Highlights AAV Gene Therapy Scale-Up and CNS Delivery Focus - TipRanks
Forge Biologics Highlights AAV Gene Therapy Scale-Up and CNS Delivery Focus  TipRanks
Source →
general 2026-02-17
Forge Biologics Highlights Technical Focus in AAV Gene Therapy Manufacturing - TipRanks
Forge Biologics Highlights Technical Focus in AAV Gene Therapy Manufacturing  TipRanks
Source →
regulatory 2026-02-17
Forge Biologics Emphasizes Industrial-Scale AAV Gene Therapy Expertise - TipRanks
Forge Biologics Emphasizes Industrial-Scale AAV Gene Therapy Expertise  TipRanks
Source →
general 2026-02-12
Forge Biologics Expands Upstream Gene Therapy Process Development Team - TipRanks
Forge Biologics Expands Upstream Gene Therapy Process Development Team  TipRanks
Source →
general 2026-02-12
Forge Biologics Targets Senior Upstream Scientist to Bolster AAV Manufacturing - TipRanks
Forge Biologics Targets Senior Upstream Scientist to Bolster AAV Manufacturing  TipRanks
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs →